Dermacell AWM® in the Treatment of Large Diabetic Foot Ulcers with Exposed Tendon and Bone. Advances in Skin & Wound Care, August 2019.
This study included 47 diabetic patients suffering from non-healing ulcers lasting 4 months on average. Mean ulcer size was 29cm2 with 96% of patients having exposed bone. All patients achieved 100% granulation at a mean of 4 weeks. An average of 1.2 applications of Dermacell AWM were used. At 16 weeks, the average reduction of wound area was 80.3%. No complications were associated with use of Dermacell AWM. This study demonstrates how effective just one application of Dermacell AWM is at healing large complex DFUs with exposed bone.
A Prospective, Multicenter, Single-Arm Clinical Trial for Treatment of Complex Diabetic Foot Ulcers with Deep Exposure Using Acellular Dermal Matrix. Advances in Skin & Wound Care, 2019, Volume 32, Number 8
With an average of 1.2 applications of Dermacell AWM®, 100% of patients achieved 100% granulation by 16 weeks. The average time to 100% granulation was 4.0 ± 2.2 weeks. There was 80.3% (from mean 29 cm^2 to 5.7 cm^2) reduction of wound surface area by week 16.
A randomized clinical trial of DermACELL AWM® in the treatment of diabetic foot ulcers. Wound Repair and Regeneration, May 2017
Four weeks after the termination of the study, 100% of wounds treated with one application of Dermacell AWM remained healed compared to 87% of wounds treated with conventional care.
Treatment of a Venous Leg Ulcer using DermACELL®, a Human Acellular Dermal Matrix (ADM)
Wound closed by 3 months post-operative.
Treatment of Diabetic Foot Ulcer with Human Acellular Dermal Matrix (ADM)
Wound was completely healed by 5 months.